Vobramitamab duocarmazine clinical trials
Also written MGC018.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses vobramitamab duocarmazine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses vobramitamab duocarmazine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung CancerActive, not recruitingPhase 2Georgetown UniversityNCT06227546Written as MGC018
- A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid TumorsTerminatedPhase 2MacroGenicsNCT05551117Written as vobramitamab duocarmazine 2.0 mg (Arm A)
- A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid TumorsCompletedPhase 1MacroGenicsNCT05293496Written as vobramitamab duocarmazine
- MGC018 With or Without MGA012 in Advanced Solid TumorsTerminatedPhase 1/2MacroGenicsNCT03729596Written as vobramitamab duocarmazine
Codes
What other systems call vobramitamab duocarmazine · ClinicalTrials.gg INT014559
- UNII (FDA) 2ZK3D69DQJVOBRAMITAMAB DUOCARMAZINEOne source FDA
- NCI Thesaurus C159495Vobramitamab DuocarmazineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2ZK3D69DQJ | VOBRAMITAMAB DUOCARMAZINE | One source FDA |
| NCI Thesaurus | C159495 | Vobramitamab Duocarmazine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.